A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose

PURPOSE: To determine the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), safety, pharmacokinetics, and pharmacodynamics of SB-743921 when administered as a 1-h infusion every 21 days to patients with advanced solid tumors or relapsed/refractory lymphoma. METHODS: Patients who failed pri...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Holen, Kyle D., Belani, Chandra P., Wilding, George, Ramalingam, Suresh, Volkman, Jennifer L., Ramanathan, Ramesh K., Vasist, Lakshmi S., Bowen, Carolyn J., Hodge, Jeffrey P., Dar, Mohammed M., Ho, Peter T. C.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2010
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4160065/
https://ncbi.nlm.nih.gov/pubmed/20461380
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-010-1346-5
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi